Miragen
miRagen Refines Regulatory Strategy for MicroRNA-targeting Drug in T-cell Lymphomas
Awaiting data from the Phase II SOLAR trial, miRagen is looking to potentially advance cobomarsen into registration-enabling studies for miR-155 elevated CTCL and ATLL.